Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Aug 8;2(4):310-4.
doi: 10.1016/j.jdcr.2016.05.004. eCollection 2016 Jul.

Recapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab

Prativa S Jayasekera  1 , Richard A Parslew  1 , Ali Al-Sharqi  1
Affiliations
Case Reports

Recapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab

Prativa S Jayasekera et al. JAAD Case Rep. .
No abstract available

Keywords: ADA, antidrug antibodies; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; biological therapy; psoriasis; ustekinumab.

PubMed Disclaimer

Figures

Fig 1
Fig 1
A Kaplan-Meier plot compares our 7 patients (current study) with those of Gniadecki et al (cohort group).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Carrascosa J.M., van Doorn M.B., Lahfa M., Nestle F.O., Jullien D., Prinz J.C. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. J Eur Acad Dermatol Venereol. 2014;28(11):1424–1430. - PubMed
    1. Warren R.B., Smith C.H., Yiu Z.Z. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) J Invest Dermatol. 2015;135(11):2632–2640. - PubMed
    1. Esposito M., Gisondi P., Cassano N. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666–672. - PubMed
    1. Gniadecki R., Bang B., Bryld L.E., Iversen L., Lasthein S., Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–252. - PubMed
    1. Hsu L., Snodgrass B.T., Armstrong A.W. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261–273. - PubMed

Publication types

LinkOut - more resources